Advertisement

Person › Details
Axel Hoos (Scorpion Therapeutics Inc.)
Hoos, Axel (Scorpion Therapeutics 202108– CEO before GSK 201406 VP Oncology RnD + Head Immuno-Oncology)
![]() |
Organisation | Scorpion Therapeutics Inc. |
Former/major organisation | GSK (Group) | |
![]() |
Product | cancer immunotherapy (immuno-oncology, I-O) |
Product 2 | oncology | |
Record changed: 2023-04-05 |
Advertisement

More documents for Axel Hoos
- [1] Scorpion Therapeutics, Inc.. (4/4/23). "Press Release: Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer". Bost...
- [2] Scorpion Therapeutics, Inc.. (1/13/22). "Press Release: Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets". Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top